MBF Therapeutics
MBF Therapeutics is an immunotherapeutic animal health company focused on creating disruptive products for infectious disease and cancer using its innovative T-Max™ DNA vaccine platform. The company aims to develop highly efficacious, universal vaccines with translational opportunities in humans, addressing serious threats in animal and human health through its proprietary platform and strategic collaborations.
Industries
Nr. of Employees
small (1-50)
MBF Therapeutics
Ambler, Pennsylvania, United States, North America
Products
DNA-based T‑cell vaccine platform
A platform combining plasmid DNA encoding multiple T‑cell antigens, immunomodulators and calcium phosphate nanoparticle formulation to generate durable cellular immunity.
SARS‑CoV‑2 DNA T‑cell vaccine candidate
A multi‑antigen plasmid DNA vaccine candidate formulated for mucosal delivery and designed to elicit broad T‑cell responses against conserved SARS‑CoV‑2 antigens.
Swine vaccine candidates (including PRRS and influenza)
Gene‑based, T‑cell directed vaccine candidates for porcine reproductive and respiratory syndrome (PRRS) and swine influenza formulated with nanoparticle delivery to improve cross‑protection and reduce disease reservoirs.
Canine cancer vaccine development using nanoparticle delivery
Development program to create immunotherapeutic vaccines for canine melanoma and other cancers using plasmid DNA antigens, immunomodulators and calcium phosphate nanoparticle delivery.
DNA-based T‑cell vaccine platform
A platform combining plasmid DNA encoding multiple T‑cell antigens, immunomodulators and calcium phosphate nanoparticle formulation to generate durable cellular immunity.
SARS‑CoV‑2 DNA T‑cell vaccine candidate
A multi‑antigen plasmid DNA vaccine candidate formulated for mucosal delivery and designed to elicit broad T‑cell responses against conserved SARS‑CoV‑2 antigens.
Swine vaccine candidates (including PRRS and influenza)
Gene‑based, T‑cell directed vaccine candidates for porcine reproductive and respiratory syndrome (PRRS) and swine influenza formulated with nanoparticle delivery to improve cross‑protection and reduce disease reservoirs.
Canine cancer vaccine development using nanoparticle delivery
Development program to create immunotherapeutic vaccines for canine melanoma and other cancers using plasmid DNA antigens, immunomodulators and calcium phosphate nanoparticle delivery.
Services
Collaborative vaccine development partnerships
Design and execution of joint development programs, option and license evaluations, and coordinated research agreements to advance vaccine candidates.
Preclinical and veterinary clinical study execution
Conduct of immunogenicity studies, challenge models and early‑stage veterinary clinical trials to evaluate vaccine candidates and administration routes.
Plasmid DNA manufacturing and GMP supply facilitation
Coordination with GMP-capable manufacturers for plasmid production, formulation and scale-up to support IND-enabling studies and commercial supply.
Regulatory and IND planning support
Project management and clinical development planning for IND preparation and regulatory interactions to advance vaccine candidates.
Antigen discovery and multi‑antigen vaccine design
Identification and selection of conserved, clinically relevant T‑cell antigens and construction of multi‑antigen plasmid formulations for cross‑protective vaccines.
Collaborative vaccine development partnerships
Design and execution of joint development programs, option and license evaluations, and coordinated research agreements to advance vaccine candidates.
Preclinical and veterinary clinical study execution
Conduct of immunogenicity studies, challenge models and early‑stage veterinary clinical trials to evaluate vaccine candidates and administration routes.
Plasmid DNA manufacturing and GMP supply facilitation
Coordination with GMP-capable manufacturers for plasmid production, formulation and scale-up to support IND-enabling studies and commercial supply.
Regulatory and IND planning support
Project management and clinical development planning for IND preparation and regulatory interactions to advance vaccine candidates.
Antigen discovery and multi‑antigen vaccine design
Identification and selection of conserved, clinically relevant T‑cell antigens and construction of multi‑antigen plasmid formulations for cross‑protective vaccines.
Expertise Areas
- T‑cell vaccine development
- DNA vaccine design and plasmid engineering
- Nanoparticle-based vaccine delivery
- Antigen discovery and selection for cross-protection
Key Technologies
- Plasmid DNA vaccines
- Calcium phosphate nanoparticle delivery
- Intranasal/transmucosal vaccine delivery
- Gene‑based immunomodulators and checkpoint inhibitor constructs